Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence

Area of Science:

• Cardiology
• Electrophysiology
• Heart Failure Management

Background:

• Guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT) significantly benefit patients with heart failure.
• Current implantable cardioverter-defibrillator (ICD) trials primarily use left ventricular ejection fraction (LVEF) for risk stratification.
• LVEF alone is insufficient for predicting sudden cardiac death (SCD) in non-ischemic cardiomyopathy (NICM), as many SCD events occur with LVEF >30%.

Purpose of the Study:

• To review the current evidence on the efficacy of ICDs in non-ischemic cardiomyopathy (NICM) patients.
• To evaluate the role of GDMT and CRT in modifying the benefit of ICDs.
• To explore improved risk stratification methods for ICD implantation in NICM beyond LVEF.

Main Methods:

• Review of recent clinical evidence and trials, including the DANISH study.
• Analysis of factors influencing ICD benefit in NICM.
• Discussion of limitations of LVEF as a sole predictor of SCD.

Main Results:

• ICDs may not provide a mortality benefit in NICM patients already receiving optimal GDMT and CRT.
• LVEF is an inadequate predictor of SCD in NICM.
• Factors like life expectancy, comorbidities, advanced heart failure, NICM etiology, and myocardial fibrosis are crucial for risk stratification.

Conclusions:

• Risk stratification for ICD implantation in NICM requires a multi-faceted approach beyond LVEF.
• Genetics and biomarkers show promise for enhancing risk assessment in NICM patients.
• Optimizing GDMT and CRT may alter the risk-benefit profile of ICDs in NICM.